Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice

OBJECTIVE: Non–Fc-binding anti-CD3–specific antibodies represent a promising therapy for preserving C-peptide production in subjects with recent-onset type 1 diabetes. However, the mechanisms by which anti-CD3 exerts its beneficial effect are still poorly understood, and it is questionable whether t...

Descripción completa

Detalles Bibliográficos
Autores principales: Valle, Andrea, Jofra, Tatiana, Stabilini, Angela, Atkinson, Mark, Roncarolo, Maria-Grazia, Battaglia, Manuela
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661605/
https://www.ncbi.nlm.nih.gov/pubmed/19151201
http://dx.doi.org/10.2337/db08-1432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661605/
https://www.ncbi.nlm.nih.gov/pubmed/19151201
http://dx.doi.org/10.2337/db08-1432

Ejemplares similares